CClinicalTrials.gg
Status unknownNCT05507268Updated Aug 18, 2022

Predictive Nomogram for Postoperative Acute Kidney Injury in Older Patients Undergoing Noncardiac Surgery

An observational study in Postoperative Acute Kidney Injury, sponsored by Chinese PLA General Hospital. Status unknown at 1 site in China. Open to participants aged 65 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-08-18.

Sponsored by Chinese PLA General Hospital · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50,000
Ages
65 Years to 120 Years
Sex
All
01

Study summary

Postoperative acute kidney injury is associated increased risk of morbidity and mortality. Older patients are at high risk of developing postoperative acute kidney injury. However, the incidence and associations of postoperative acute kidney injury in older patients are not well understood. This study aims to develop and validate a predictive nomogram for postoperative acute kidney injury in older patients undergoing noncardiac surgery.

Read the detailed description

Postoperative acute kidney injury (AKI) affects approximately 2% to 40% of patients undergoing cardiac and major noncardiac surgeries.

Older patients are more susceptible to renal impairment than younger patients. However, the incidence and associations of AKI in older patients are rarely understood.

Generally, in-depth knowledge of risk factors and thus able to identify patients at high risk to develop postoperative AKI is essential to optimize perioperative prevention and protection strategies.

In this retrospective study, the investigators intend to develop and validate a predictive model for postoperative using the identified risk factors.

The primary outcome is postoperative AKI, which according to the Kidney Disease: Improving Global Outcomes (KDIGO) criterion, is defined as an absolute increase in serum creatinine of 0.3 mg/dL within 48 hours or a 1.5-fold increase from preoperative baseline within 7 days after surgery.

02

Conditions studied

  • Postoperative Acute Kidney Injury

Keywords

  • prediction model
  • nomogram
  • older
  • noncardiac surgery
03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's planned enrollment of 50,000 is above the median of 150 across 773 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Older patients (aged ≥ 65 years) undergoing noncardiac surgery from 2012-2019

Inclusion criteria

  • Patients aged 65 years and older

Exclusion criteria

Exclusion Criteria:

  • Emergency operation
  • Cardiac surgery
  • Incomplete data
  • Incomplete data
  • Local anesthesia
  • Preoperative renal failure or requirement for dialysis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • older patients undergoing noncardiac surgery

    older patients (aged ≥65 years) scheduled for noncardiac surgery

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. acute kidney injury

    an absolute increase in serum creatinine of 0.3 mg/dl within 48 hours or a 1.5-fold increase from preoperative baseline within 7 days after surgery

    Time frame: 7 days after surgery

07

Study locations

1 of 1 sites recruiting
  • the First Medical Center of Chinese PLA General Hospital
    Beijing, Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05507268
Lead sponsor
Chinese PLA General Hospital
Responsible party
Weidong Mi (Director (Cheif expert of National key research and development program of China 2018YFC2001900), Chinese PLA General Hospital) — Principal investigator
First posted
Aug 18, 2022
Start date
Apr 1, 2022
Primary completion
Dec 30, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
Aug 18, 2022

Study contacts

Weidong Mi, PhD
Contact
wwdd1962@163.com
8613381082966
Yao Yu, PhD
Contact
18501088975@163.com
8618501088975
Weidong Mi, PhD
principal investigator · The First Medical Center of Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion